Skip to main content

Table 1 Comparison of baseline clinical demographics of test and control groups

From: Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins: results of an open-labelled pilot study

  Control Group Test Group P
Categories (N = 18) (N = 18)  
Clinical assessment at entry    
Age (Years) 62.8 ± 11.4 59.7 ± 14.9 NS
RA duration (Months) 88.1 ± 76.2 114.5 ± 92.6 NS
DAS28-ESR 5.64 ± 0.86 5.64 ± 1.37 NS
TJC 12.3 ± 6.1 15.9 ± 11.7 NS
SJC 12.6 ± 6.2 13.9 ± 7.8 NS
ESR (mm/hr) 46.7 ± 27.0 48.4 ± 32.9 NS
CRP (mg/dl) 2.5 ± 2.4 2.5 ± 2.8 NS
RF (IU/ml) 143 ± 102 213 ± 292 NS
Medication    
PSL (mg/day) 2.72 ± 2.29 2.64 ± 2.94 NS
PSL (No.) 13 11 NS§
DMARDs (No.) 16 13 NS§
NSAIDs (No.) 14 11 NS§
Ochi's Classification
LES 3 (17%) 4 (22%) NS§
MES 12 (66%) 10 (56%) NS§
MUD 3 (17%) 4 (22%) NS§
Complications and risk factor
Complication (No.) 9 9 NS§
Drug resistance (No.) 7 5 NS§
Drug allergy (No.) 2 4 NS§
Gastrointestinal Disorders    
Constipation (No.) 12 12 NS§
Diarrhea (No.) 3 2 NS§
None (No.) 3 4 NS§
  1. Data is shown as the mean ± standard deviation.
  2. TJC: tender joint count, SJC: swollen joint count, RF: rheumatoid factor, PSL: Prednisolone, LES: least erosive subset, MES: more erosive subset, MUD: mutilating disease, NS: Not significant.
  3. †: Determined by Mann Whitney U-test. §: Determined by Chi square test.